Longitudinal Changes in Health-Related Quality of Life in Primary Glomerular Disease: Results From the CureGN Study.

Journal Article (Journal Article)

INTRODUCTION: Prior cross-sectional studies suggest that health-related quality of life (HRQOL) worsens with more severe glomerular disease. This longitudinal analysis was conducted to assess changes in HRQOL with changing disease status. METHODS: Cure Glomerulonephropathy (CureGN) is a cohort of patients with minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, IgA vasculitis, or IgA nephropathy. HRQOL was assessed at enrollment and follow-up visits 1 to 3 times annually for up to 5 years with the Patient-Reported Outcomes Measurement Information System (PROMIS). Global health, anxiety, and fatigue domains were measured in all; mobility was measured in children; and sleep-related impairment was measured in adults. Linear mixed effects models were used to evaluate HRQOL responsiveness to changes in disease status. RESULTS: A total of 469 children and 1146 adults with PROMIS scores were included in the analysis. HRQOL improved over time in nearly all domains, though group-level changes were modest. Edema was most consistently associated with worse HRQOL across domains among children and adults. A greater number of symptoms also predicted worse HRQOL in all domains. Sex, age, obesity, and serum albumin were associated with some HRQOL domains. The estimated glomerular filtration rate (eGFR) was only associated with fatigue and adult physical health; proteinuria was not associated with any HRQOL domain in adjusted models. CONCLUSION: HRQOL measures were responsive to changes in disease activity, as indicated by edema. HRQOL over time was not predicted by laboratory-based markers of disease. Patient-reported edema and number of symptoms were the strongest predictors of HRQOL, highlighting the importance of the patient experience in glomerular disease. HRQOL outcomes inform understanding of the patient experience for children and adults with glomerular diseases.

Full Text

Duke Authors

Cited Authors

  • Murphy, SL; Mahan, JD; Troost, JP; Srivastava, T; Kogon, AJ; Cai, Y; Davis, TK; Fernandez, H; Fornoni, A; Gbadegesin, RA; Herreshoff, E; Canetta, PA; Nachman, PH; Reeve, BB; Selewski, DT; Sethna, CB; Wang, C-S; Bartosh, SM; Gipson, DS; Tuttle, KR; CureGN Consortium,

Published Date

  • October 2020

Published In

Volume / Issue

  • 5 / 10

Start / End Page

  • 1679 - 1689

PubMed ID

  • 33102960

Pubmed Central ID

  • PMC7569685

Electronic International Standard Serial Number (EISSN)

  • 2468-0249

Digital Object Identifier (DOI)

  • 10.1016/j.ekir.2020.06.041


  • eng

Conference Location

  • United States